S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NYSE:PBH

Prestige Consumer Healthcare Stock Forecast, Price & News

$57.97
+2.00 (+3.57%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$56.28
$59.17
50-Day Range
$55.92
$63.12
52-Week Range
$37.35
$63.83
Volume
309,813 shs
Average Volume
197,244 shs
Market Capitalization
$2.90 billion
P/E Ratio
16.38
Dividend Yield
N/A
Beta
0.7
30 days | 90 days | 365 days | Advanced Chart
Receive PBH News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.


Prestige Consumer Healthcare logo

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Headlines

Prestige Consumer Healthcare (NYSE:PBH) Trading 4.4% Higher
January 21, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
CUSIP
74112D10
Employees
505
Year Founded
N/A

Sales & Book Value

Annual Sales
$943.36 million
Cash Flow
$3.88 per share
Book Value
$27.24 per share

Profitability

Net Income
$164.68 million
Pretax Margin
22.51%

Debt

Price-To-Earnings

Miscellaneous

Free Float
49,352,000
Market Cap
$2.90 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/23/2022
Next Earnings (Confirmed)
2/03/2022
Fiscal Year End
3/31/2022

MarketRank

Overall MarketRank

1.98 out of 5 stars

Consumer Discretionary Sector

205th out of 391 stocks

Pharmaceutical Preparations Industry

319th out of 685 stocks

Analyst Opinion: 3.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -












Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions

Is Prestige Consumer Healthcare a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Prestige Consumer Healthcare stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBH, but not buy additional shares or sell existing shares.
View analyst ratings for Prestige Consumer Healthcare
or view top-rated stocks.

How has Prestige Consumer Healthcare's stock price been impacted by COVID-19?

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBH shares have increased by 61.4% and is now trading at $57.97.
View which stocks have been most impacted by COVID-19
.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Prestige Consumer Healthcare
.

How can I listen to Prestige Consumer Healthcare's earnings call?

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, February 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "4798187".

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its earnings results on Thursday, November, 4th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.03. The business earned $276.23 million during the quarter, compared to the consensus estimate of $261.23 million. Prestige Consumer Healthcare had a net margin of 17.56% and a trailing twelve-month return on equity of 13.71%. The firm's revenue was up 16.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 EPS.
View Prestige Consumer Healthcare's earnings history
.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its FY 2022 earnings guidance on Thursday, November, 18th. The company provided EPS guidance of $3.930-$3.980 for the period, compared to the Thomson Reuters consensus estimate of $3.980. The company issued revenue guidance of $1.05 billion-$1.06 billion, compared to the consensus revenue estimate of $1.05 billion.

What price target have analysts set for PBH?

2 analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's shares. Their forecasts range from $63.00 to $126.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $94.50 in the next year. This suggests a possible upside of 63.0% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare
or view top-rated stocks among Wall Street analysts.

Who are Prestige Consumer Healthcare's key executives?

Prestige Consumer Healthcare's management team includes the following people:
  • Ronald M. Lombardi, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • Jeff Zerillo, Senior Vice President-Operations
  • Christine Sacco, Chief Financial Officer
  • William C. P'Pool, Secretary, Senior Vice President & General Counsel
  • Adel Mekhail, Executive Vice President-Marketing & Sales

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Prestige Consumer Healthcare's key competitors?

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nordea Investment Management AB (0.27%), Russell Investments Group Ltd. (0.13%), Trust Co. of Vermont (0.08%), State of Alaska Department of Revenue (0.07%), M&G Investment Management Ltd. (0.06%) and Louisiana State Employees Retirement System (0.05%). Company insiders that own Prestige Consumer Healthcare stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare
.

Which major investors are selling Prestige Consumer Healthcare stock?

PBH stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Diversified Trust Co, Nordea Investment Management AB, State of Alaska Department of Revenue, Trust Co. of Vermont, Russell Investments Group Ltd., and Parallel Advisors LLC. Company insiders that have sold Prestige Consumer Healthcare company stock in the last year include Mary Beth Fritz, and Ronald M Lombardi.
View insider buying and selling activity for Prestige Consumer Healthcare
or view top insider-selling stocks.

Which major investors are buying Prestige Consumer Healthcare stock?

PBH stock was acquired by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Ritholtz Wealth Management, Veriti Management LLC, Crossmark Global Holdings Inc., and Louisiana State Employees Retirement System.
View insider buying and selling activity for Prestige Consumer Healthcare
or or view top insider-buying stocks.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $57.97.

How much money does Prestige Consumer Healthcare make?

Prestige Consumer Healthcare has a market capitalization of $2.90 billion and generates $943.36 million in revenue each year. The company earns $164.68 million in net income (profit) each year or $3.54 on an earnings per share basis.

How many employees does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare employs 505 workers across the globe.

What is Prestige Consumer Healthcare's official website?

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Where are Prestige Consumer Healthcare's headquarters?

Prestige Consumer Healthcare is headquartered at 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at (914) 524-6800, via email at [email protected], or via fax at 302-674-5266.


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.